William R. Sugrue

https://assets.montefioreeinstein.org/profiles/images/physphoto/Sugrue_William_MD_420x504.jpg

First Name

William

Last Name

Sugrue

NPI

1356737258

Faculty ID

16614

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

52940

Is Open Scheduling

Off

Elayna O. Rubens

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/9d098ab0-8fa8-11ee-8c04-11a56f4c94fe.jpg

First Name

Elayna

Last Name

Rubens

NPI

1578723268

Faculty ID

16790

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

33119

Is Open Scheduling

Off

Solomon L. Moshe

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/c0b77720-090c-11ed-9bb9-9f5f9d7bb274.jpg

First Name

Solomon

Last Name

Moshe

NPI

1396820619

Faculty ID

6831

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoBodyText" style="margin: 1.95pt 8.45pt 0.0001pt 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><strong>Solomon L. Mosh&eacute;, M.D., </strong>is the Charles Frost Chair in Neurosurgery and Neurology, and Professor of Neurology, Neuroscience, and Pediatrics at the Albert Einstein College of Medicine/Montefiore Medical Center in the Bronx, New York. He is also the Vice Chair of the Saul R. Korey Department of Neurology, Director of the Isabelle Rapin Child Neurology Division and Director of Clinical Neurophysiology. His area of expertise is in epilepsy and related disorders.</p>
<p class="MsoBodyText" style="margin: 1.95pt 8.45pt 0.0001pt 6pt; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;"><span style="font-size: 12pt;">Since 1979, his research has focused on understanding the mechanisms underlying age and sex-related differences in epilepsy in humans and animal models.&nbsp; Current research interests include studies on the role of subcortical circuitries involved in the control of seizures as a function of age and sex; the consequences of seizures on the developing brain and the development of models of catastrophic epilepsies. His laboratory has patented a model of infantile spasms that can be used to identify novel treatments. He is co principal investigator of a Center Without Walls grant on interdisciplinary research aimed at accelerating the development of disease modifying or prevention therapies for epilepsy following traumatic brain injuries. He is also involved in a large multicenter study examining the consequences of prolonged febrile seizures.&nbsp; He has over 600 publications as well as He has over 600 publications as well over 35 books and monographs.</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;"><span style="font-size: 12pt;">over 35 books and monographs.</span></p>
<p class="MsoBodyText" style="margin: 0.55pt 0in 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoBodyText" style="margin: 0.05pt 5.85pt 0.0001pt 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;He has served as President of the International League Against Epilepsy (2009-2013), the American Epilepsy Society (2000-2001), the American Clinical Neurophysiology Society (1996-1997) and the Eastern Association of EEGers (1992-1994). He is the recipient of many awards and honors, including the Teacher-Investigator Development Award from NINDS; the 1995 Jacob Javits Neuroscience Investigator Award from NINDS; the 1984 Michael Prize for Achievements in Epilepsy Research; the 1990 American Epilepsy Society Research Award; the 1999 Ambassador for Epilepsy Award from the International League Against Epilepsy; the 2005 Gloor Award from the American Clinical Neurophysiology Society; the 2007 J.E. Purkyne Honorary Medal in Biomedical Research by the Czech Academy of Sciences; the 2008 Mentor of the Year Award from Albert Einstein College of Medicine; the 2010 Global and Awareness Award from CURE, Citizens United for Research in Epilepsy; the First 2012 Saul R. Korey Award in Translational Science and Medicine, Albert Einstein College of Medicine and the 2017 Bernard Sachs Award from the Child Neurology Society, <span style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">and the 2023 Lifetime Achievement Award from the International League against Epilepsy.</span></p>
<p class="MsoBodyText" style="margin: 0.05pt 5.85pt 0.0001pt 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoBodyText" style="margin: 0.05pt 5.85pt 0.0001pt 0in; font-size: 12pt; font-family: Calibri, sans-serif;">He has been asked to deliver over 50 several keynote lectures.</p>
<p class="MsoBodyText" style="margin: 0.05pt 5.85pt 0.0001pt 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="color: red;">&nbsp;</span></p>
<p class="MsoBodyText" style="margin: 0.05pt 5.85pt 0.0001pt 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Clinical Focus:</p>
<p class="MsoBodyText" style="margin: 0.05pt 5.85pt 0.0001pt 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Dr. Mosh&eacute; focuses on helping people with epilepsy and related conditions with a special emphasis on children and adolescents.</p>
<p class="MsoBodyText" style="margin: 0.05pt 5.85pt 0.0001pt 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="color: red;">&nbsp;</span></p>
<p class="MsoBodyText" style="margin: 0.05pt 5.85pt 0.0001pt 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="color: #002060;">Research focus</span></p>
<p class="MsoBodyText" style="margin: 0.05pt 5.85pt 0.0001pt 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Dr Mosh&eacute; has focused on translational research to understand the mechanisms underlying age and sex-related differences in epilepsy in humans and animal models. The main goals are to develop individualized treatments today and to prevent and cure epilepsy tomorrow. Current projects include the development of effective means to predict and treat epilepsy after traumatic brain injury and the development of specialized treatments for infants and children with epilepsy.</p>

Research Areas

Expert Tags

Areas of Expertise

Expert Summary

<p class="MsoNormal" style="line-height: 15.6pt;"><span style="font-size: 9.0pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;">Dr.&nbsp;Mosh&eacute; is an authority on the mechanisms that underlie the development of epilepsy and on the consequences of the disease in infants and children.</span></p>
<p class="MsoNormal" style="line-height: 15.6pt;"><span style="font-size: 9.0pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;">A translational scientist, Dr. Mosh&eacute; has developed and patented an animal model that replicates human infantile spasms, which can be used to identify novel treatments of this devastating condition. Dr. Mosh&eacute; has served as President of the International League Against Epilepsy, American Epilepsy Society, the American Clinical Neurophysiology Society, and the Eastern Association of Electroencephalographers.</span></p>
<p class="MsoNormal" style="line-height: 15.6pt;"><span style="font-size: 9.0pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;">Dr. Mosh&eacute; is actively involved in several large, multicenter studies examining the outcomes of prolonged febrile seizure to identify predictive biomarkers of the course of these conditions and response to treatment.</span></p>
<p class="MsoNormal" style="line-height: 15.6pt;"><span style="font-size: 9.0pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;">Dr. Mosh&eacute;&nbsp;has received numerous honors and awards, including the American Epilepsy Society Research Recognition Award,&nbsp;Jacob Javitz Neuroscience Investigator Award from the National Institutes of Health, the Michael Prize,&nbsp;&nbsp;American Epilepsy Society research award, the CURE (Citizens United for Research in Epilepsy)&nbsp;&nbsp;Global Awareness Award for leadership in raising the international profile of epilepsy<strong>,&nbsp;</strong>the Pierre Gloor Award of the American Clinical Neurophysiology Society, and the J.E. Purkyne Honorary Medal for Merit in the BioMedical Sciences of the Czech Academy of Sciences. He is an elected member of the American Neurological Association and the American Pediatric Society. &nbsp;</span></p>

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

Dr. Mosh&eacute; focuses on helping people with epilepsy and related conditions with a special emphasis on children and adolescents

Research Focus

Dr. Mosh&eacute; has focused on translational research to understand the mechanisms underlying age and sex-related differences in epilepsy in human and animal models. The main goals are to develop individualized treatments today and to prevent and cure epilepsy tomorrow. Current projects include the development of effective means to predict and treat epilepsy after traumatic brain injury and the development of specialized treatments for infants and children with epilepsy.

Elsevier Profile

Selected Publications

<ol>
<li>&nbsp;<span style="font-size: 11pt; font-family: Arial, sans-serif;">Katsarou A, Mosh&eacute; SL, Galanopoulou AS.&nbsp; Interneuronopathies and their role in early life epilepsies and neurodevelopmental disorders.&nbsp;&nbsp; Epilepsia Open 3: 284-306 (2017). PMID: 29062978</span></li>
<li><span style="font-size: 11pt; font-family: Arial, sans-serif;">Moshe SL.&nbsp; The 2017 Sachs lecture: Kindling knowledge in Epilepsy.&nbsp; Pediatric Neurology 85: 5-12 (2018).&nbsp; PMID: 29958806</span></li>
<li>Saletti PG, Ali I, Casillas-Espinonsa PM, Semple BD, Lisgaras C, Moshe SL, Galanopoulou AS. In search of antiepileptogenic treatments for post-traumatic epilepsy.&nbsp; Neurobiology of Disease 123: 86-99 (2019).&nbsp; PMID: 29936231</li>
<li>Correa DJ, Kwon C, Connors S, Fureman B, Whittemore V, Jette N, Mathern G and Moshe SL.&nbsp;&nbsp; For the EpiBioS4RX Public Engagement Core.&nbsp;&nbsp; Applying participatory action research in traumatic brain injury studies to prevent post-traumatic epilepsy.&nbsp;&nbsp; Neurobiology of Disease 123: 137-144 (2019).&nbsp; PMID: 30031158</li>
<li><span style="font-size: 11pt; font-family: Arial, sans-serif;">Molinero I, Galanopoulou AS and Moshe SL.&nbsp;&nbsp; Rodent models: Where it all started with these &ldquo;truths&rdquo;.&nbsp;&nbsp; European Journal of Paediatric Neurology 61-65 (2020) PMID: 31875833</span></li>
<li><span style="font-size: 11pt; font-family: Arial, sans-serif;">Ozlem A, Briggs S, Mowrey W, Moshe SL, Galanopoulou AS&nbsp;&nbsp; Antiepiletogenic effects of rapamycin in a model of infantile spasms due to structural lesions.&nbsp;&nbsp; Epilepsia, 62,1985-1999, (2021) PMID: 34212374</span></li>
<li>
<p class="MsoNormal" style="margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Zuberi S, Wirrell E, Yozawitz E, Wilmshurst J, Specchi N, Riney K, Pressler R, Auvin S, Samia P, Hirsch E, Galicchio S, Triki C, Snead O, Wiebe S, Cross H, Tinuper P, Scheffer I, Perucca E and Moshe SL.&nbsp;&nbsp; ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions.&nbsp; Epilepsia, 63, 1349-1397 (2022) PMID: 35503712</span></p>
</li>
<li>
<p class="MsoNormal" style="margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Hirsch E, French J, Scheffer I, Bogacz A, Alsaadi T, Sperling M, Abdulla F, Zuberi S, Trinka E, Specchio N, Somerville E, Samia P, Riney K, Nabbout R, Jain S, Wilmshurst J, Auvin S, Wiebe S, Perucca E, Moshe SL, Tinuper P and Wirrell E.&nbsp; ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions.&nbsp; Epilepsia, 63, 1475-1499 (2022) PMID: 35503716</span></p>
</li>
<li>
<p class="MsoNormal" style="margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Specchio N, Wirrell E, Scheffer I, Nabbout R, Riney K, Samia P, Guerreiro M, Gwer S, Zuberi S, Wilmshurst J, Yozawitz E, Pressler R, Hirsch E, Wiebe S, Cross H, Perucca E, Moshe SL, Tinuper P and Auvin S.&nbsp; International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions.&nbsp; Epilepsia, 63, 1398-1442 (2022) PMID: 35503717</span></p>
</li>
<li>
<p class="MsoNormal" style="margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">&nbsp;Riney K, Bogacz A, Somerville E, Hirsch E, Nabbout R, Scheffer I, Zuberi S, Alsaadi T, Jain S, French J, Specchio N, Trinka E, Wiebe S, Auvin S, Cabral-Lin L, Naiddo A, Perucca E, Moshe SL, Wirrell E and Tinuper P.&nbsp; International League Againist Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE Task Force on Nosology and Definitions.&nbsp;&nbsp; Epilespia, 63, 1443-1474 (2022) PMID: 35503725</span></p>
</li>
<li>
<p class="MsoNormal" style="margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Wirrell E, Nabbout R, Scheffer I, Alsaadi T, Bogacz A, French J, Hirsch E, Jain S, Kaneko S, Riney K, Samia P, Snead O, Somerville E, Specchio N, Trinka E, Zuberi S, Balestrini S, Wiebe S, Cross H, Perucca E, Moshe SL and Tinuper P.&nbsp;&nbsp; Methodology for classification and definition of epilepsy syndromes with list of syndroms: Report of the ILAE Task Force on Nosology and Definitions.&nbsp;&nbsp; Epilepsia, 63, 1333-1348 (2022) PMID: 35503715</span></p>
</li>
<li>
<p class="MsoNormal" style="margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Saletti P, Casillas-Espinosa P, Lisgaras C, Mowrey W, Li Q, Liu W, Brady R, Ali I, Silva J, Yamakawa G, Hudson M, Li C, Braine E, Coles L, Cloyd J, Shultz S, Mosh&eacute; SL, O&rsquo;Brien T, Galanopoulou AS for the EpiBioS4RX Group.&nbsp;&nbsp;&nbsp; TAU phosphorylation patterns in the rat cerebral cortex after traumatic brain injury and sodium selenate effects:&nbsp; An EpiBioS4Rx Project 2 study.&nbsp;&nbsp; Journal of Neurotrauma pgs 1-22, (2023.) &nbsp;PMID: 36950806</span></p>
</li>
<li>
<p class="MsoNormal" style="margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Saletti P, Mowrey W, Liu W, Li Q, McCullough J, Aniceto R, Lin I-H, Eklund M, Casillas-Espinosa P, Ali I, Santana-Gomez C, Coles L, Shultz S, Jones N, Staba R, O&rsquo;Brien T, Mosh&eacute; SL, Agoston D, Galanopoulou AS for the EpiBioS4RX Study Group.&nbsp;&nbsp;&nbsp;&nbsp; Early preclinical plasma protein biomarkers of brain trauma are influenced by early seizures and levetiracetam.&nbsp;&nbsp; Epilepsia Open pgs. 586-608 (2023) PMID: 37026764</span></p>
</li>
<li>
<p class="MsoNormal" style="margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Coles L, Saletti P, Lisgaras C, Casillas-Espinosa P, Liu W, Li Q, Jones N, Shultz S, Ali I, Brady R, Yamakawa G, Hudson M, Silva J, Braine E, Mishra U, Cloyd J, O&rsquo;Brien T, Mosh&eacute; SL, Galanopoulou AS for the EpiBioS4RX Study Group.&nbsp;&nbsp; Levetiracetam Pharmacokinetics and Brain Uptake in a Lateral Fluid Percussion Injury Rat Model.&nbsp;&nbsp; <span style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">Journal of Pharmacology and Experimental Therapeutics pgs 1-30, (2023). &nbsp;PMID:</span> </span><span style="font-size: 11pt; font-family: Arial, sans-serif; color: #212121;">37316328</span></p>
</li>
</ol>

EMR ID

3412

Biography

<p>Solomon L. Mosh&eacute;, MD, is Vice Chair of Neurology, Director of the Isabelle Rapin Child Neurology Division and Director of Clinical Neurophysiology at Montefiore. He is also the Charles Frost Chair in Neurosurgery and Neurology, Vice Chair, Saul R. Korey Department of Neurology, and Professor of Neurology, Neuroscience and Pediatrics at the Albert Einstein College of Medicine (Einstein). Dr. Mosh&eacute;&rsquo;s clinical focus is on epilepsy and electroencephalography with special emphasis on age-related influences on the expression, control and consequences of seizures.</p><p>After receiving his Doctor of Medicine from the National University of Athens School of Medicine in Greece in 1972, Dr. Mosh&eacute; began his post-doctoral training at the University Hospital of Maryland. He completed his internship and residency there in pediatrics in 1975. Following this, he pursued a pediatric neurology fellowship at Einstein from 1975 to 1978. He was a visiting epilepsy research fellow at the University of California Los Angeles in 1978, then completed a neurology and neuroscience research fellowship at Einstein in 1979. He was a guest scholar with the EEG department at Columbia Presbyterian Medical Center from 1980 to 198, and with the seizure unit at Children&rsquo;s Hospital in Boston in 1980.</p><p>Dr. Mosh&eacute;&rsquo;s research focuses on understanding the mechanisms underlying differences in epilepsy in humans and animal models. His laboratory has developed and patented a novel model of human infantile spasms that can be used to identify novel treatments of this devastating condition. He also investigates the consequences of prolonged seizures and methods to accelerate the development of disease modifying or prevention therapies for post-traumatic epilepsy. His extensive body of work has been shared nationally and internationally through peer-reviewed publications, lectures and conferences. He is a member on several editorial boards including Neurobiology of Disease, Pediatric Neurology, Epileptic Disorders, and the Journal of Neurology & Psychology.</p><p>Dr. Mosh&eacute; has been recognized with numerous national and international honors and awards, including a 1995 Jacob Javits Neuroscience Investigator Award from the National Institute of Health, the first 2012 Saul R. Korey Award in Translational Science and Medicine, Albert Einstein College of Medicine; the 2017 Bernard Sachs Award from the Child Neurology Society, and election as a foreign member of the Russian Academy of Science in 2017. He is a member of many professional societies including the American Academy of Neurology, the Child Neurology Society, the American Epilepsy Society and the American Association for Advancement of Science.</p>

Is Open Scheduling

Off

Alan D. Legatt

https://assets.montefioreeinstein.org/profiles/images/2876-alan-legatt.jpg

First Name

Alan

Last Name

Legatt

NPI

1275618951

Faculty ID

2876

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Legatt's clinical activities include intraoperative neurophysiologic monitoring, EEG-CCTV monitoring for epilepsy, and clinical EEG and evoked potential studies. His research interests include the analysis of EEG monitoring data, the subcomponent structure and generators of evoked potentials, new methods for analysis of evoked potential studies, evoked potential changes in patients with epilepsy, and techniques for intraoperative monitoring of the nervous system.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p class="MsoNormal" style="margin-left: 22.5pt; text-indent: -22.5pt;">Haut SR, Shinnar S, Legatt AD, O'Dell C, Moshe SL. The association between seizure clustering and status epilepticus in patients with intractable complex partial seizures. Epilepsia, 1999;40:1832-1834.</p>
<p class="MsoNormal" style="margin-left: 22.5pt; text-indent: -22.5pt;">Legatt AD, Kader A. Topography of the initial cortical component of the median nerve somatosensory evoked potential: relationship to central sulcus anatomy. J Clin Neurophysiol, 2000;17:321-325.</p>
<p class="MsoNormal" style="margin-left: 22.5pt; text-indent: -22.5pt;">Lado FA, Legatt AD, LaSala PA, Shinnar S. Alteration of the cortical motor map in a patient with intractable focal seizures. J Neurol Neurosurg Psychiat 2002;72:811-814.</p>
<p class="MsoNormal" style="margin-left: 22.5pt; text-indent: -22.5pt;">Legatt AD, Emerson RG. Motor evoked potential monitoring - It's about time (editorial). <span style="mso-spacerun: yes;">&nbsp;</span>J Clin Neurophysiol, 2002;19:383-386.</p>
<p class="MsoNormal" style="margin-left: 22.5pt; text-indent: -22.5pt;">Legatt AD. Mechanisms of intraoperative brainstem auditory evoked potential changes. J Clin Neurophysiol, 2002;19:396-408.</p>
<p class="MsoNormal" style="margin-left: 22.5pt; text-indent: -22.5pt;">Legatt AD. Current practice of motor evoked potential monitoring: Results of a survey. J Clin Neurophysiol, 2002;19:454-460.</p>
<p class="MsoNormal" style="margin-left: 22.5pt; text-indent: -22.5pt;">Legatt AD. Ellen R. Grass Lecture: Motor Evoked Potential Monitoring. Amer J Electroneurodiagnostic Technol, 2004;44:222-243. Legatt AD.</p>
<p class="MsoNormal" style="margin-left: 22.5pt; text-indent: -22.5pt;">Legatt AD. Pathways of Hearing and Balance. In: Van De Water T, Staecker H (Eds.), Basic Science Review for Otolaryngology. Thieme, New York, 2006:350-360.</p>
<p class="MsoNormal" style="margin-left: 22.5pt; text-indent: -22.5pt;">Lefebvre PP, Legatt AD. Assessment of Central Auditory Function. In: Van De Water T, Staecker H (Eds.), Basic Science Review for Otolaryngology. Thieme, New York, 2006:361-367.</p>
<p class="MsoNormal" style="margin-left: 22.5pt; text-indent: -22.5pt;">Legatt AD. BAEPs in Surgery. In: Nuwer, M (Ed.) Intraoperative Monitoring of Neural Function. Handbook of Clinical Neurophysiology, Volume 8; Elsevier, Amsterdam, 2008:334-349.</p>
<p class="MsoNormal" style="margin-left: 22.5pt; text-indent: -22.5pt;">Cherian K, Weidenheim K, Legatt A, Shifteh K, Abbott IR, Moshe <span style="mso-spacerun: yes;">&nbsp;</span>SL. Extensive apoptosis in a case of intractable infantile status epilepticus. Epilepsy Research, 2009;85:305-310.</p>
<p class="MsoNormal" style="margin-left: 22.5pt; text-indent: -22.5pt;">Nuwer MR, Emerson RG, Galloway G, Legatt AD, Lopez J, Minahan R, Yamada T, Goodin DS, Armon C, Chaudhry V, Gronseth GS, Harden CL.<span style="mso-spacerun: yes;">&nbsp; </span>Evidence-based guideline update: Intraoperative spinal monitoring with somatosensory and transcranial electrical motor evoked potentials: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Clinical Neurophysiology Society. Neurology, 2012; 78:585-589.</p>
<p class="MsoNormal" style="margin-left: 22.5pt; text-indent: -22.5pt;">Fried SJ, Smith DM, Legatt AD.<span style="mso-spacerun: yes;">&nbsp; </span>Median nerve somatosensory evoked potential monitoring during carotid surgery: Does reference choice matter?<span style="mso-spacerun: yes;">&nbsp; </span>J Clin Neurophysiol, 2014;31:55-57.</p>
<p class="MsoNormal" style="margin-left: 22.5pt; text-indent: -22.5pt;">Legatt AD.<span style="mso-spacerun: yes;">&nbsp; </span>Brainstem auditory evoked potentials (BAEPs). In: Aminoff M, Daroff R (Eds.),<span style="mso-spacerun: yes;">&nbsp; </span>Encyclopedia of the Neurological Sciences, 2nd Edition. Elsevier Science, San Diego, 2014, volume 1, pp. 505-508.</p>
<p class="MsoNormal" style="margin-left: 22.5pt; text-indent: -22.5pt;">Legatt AD.<span style="mso-spacerun: yes;">&nbsp; </span>Intraoperative Neurophysiology: Interactive Case Studies, (digital learning program on DVD-ROM), Demos Medical, New York, 2015.</p>
<p class="MsoNormal" style="margin-left: 22.5pt; text-indent: -22.5pt;">Legatt AD.<span style="mso-spacerun: yes;">&nbsp; </span>Brainstem auditory evoked potentials. In:<span style="mso-spacerun: yes;">&nbsp; </span>Husain AM (Ed.), A Practical Approach to Neurophysiologic Intraoperative Monitoring, 2nd Edition. Demos Medical, New York, 2015:46-54.</p>
<p class="MsoNormal" style="margin-left: 22.5pt; text-indent: -22.5pt;">Legatt AD. Electrophysiologic auditory tests. In: Celesia GG, Hickock<span style="mso-spacerun: yes;">&nbsp; </span>G (Eds.), The Human Auditory System: Fundamental Organization And Clinical Disorders. Handbook of Clinical Neurology, 3rd Series, Volume 129. Elsevier, Amsterdam, 2015:289-311.</p>
<p class="MsoNormal" style="margin-left: 22.5pt; text-indent: -22.5pt;">Legatt AD, Nuwer MR, Emerson RG.<span style="mso-spacerun: yes;">&nbsp; </span>Intraoperative monitoring of central neurophysiology.<span style="mso-spacerun: yes;">&nbsp; </span>In:<span style="mso-spacerun: yes;">&nbsp; </span>Schomer DL, Lopes da Silva, FH (Eds.) Niedermeyer's Electroencephalography: Basic Principles, Clinical Applications, and Related Fields, 7th Edition. Oxford University Press, Oxford, UK, 2018:833-866.</p>
<p class="MsoNormal" style="margin-left: 22.5pt; text-indent: -22.5pt;">Rotenberg A, Pascual-Leone A, Legatt AD. Transcranial electrical and magnetic stimulation.<span style="mso-spacerun: yes;">&nbsp; </span>In:<span style="mso-spacerun: yes;">&nbsp; </span>Schomer DL, Lopes da Silva, FH (Eds.) Niedermeyer's Electroencephalography: Basic Principles, Clinical Applications, and Related Fields, 7th Edition. Oxford University Press, Oxford, UK, 2018:723-738.</p>
<p class="MsoNormal" style="margin-left: 22.5pt; text-indent: -22.5pt;">Legatt AD, Emerson RG, Epstein CM, MacDonald DB, Deletis V, Bravo RJ, L&oacute;pez JR. ACNS Guideline: Transcranial electrical stimulation motor evoked potential monitoring. J Clin Neurophysiol, 2016;33:42-50.</p>
<p class="MsoNormal" style="margin-left: 22.5pt; text-indent: -22.5pt;">Legatt AD.<span style="mso-spacerun: yes;">&nbsp; </span>Electrophysiology of cranial nerve testing: Auditory nerve. J Clin Neurophysiol, 2018;35:25-38.<br style="mso-special-character: line-break;" /><!-- [if !supportLineBreakNewLine]--><br style="mso-special-character: line-break;" /><!--[endif]--></p>

EMR ID

3367

Is Open Scheduling

Off

Farhad Elyaderani

https://assets.montefioreeinstein.org/profiles/images/physphoto/Kadkhodaei-Elyaderani_Farhad_MD.jpg

First Name

Farhad

Last Name

Elyaderani

NPI

1396972725

Faculty ID

15528

CMO Specialties

Employment Status

Voluntary

Patient Type

Adult

Department

Gender

Male

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

69285

Is Open Scheduling

Off

Christine Hung

https://assets.montefioreeinstein.org/profiles/images/13315-christine-hung.jpg

First Name

Christine

Last Name

Hung

NPI

1699932384

Faculty ID

13315

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5589

Is Open Scheduling

Off

Steven Herskovitz

https://assets.montefioreeinstein.org/profiles/images/physphoto/Herskovitz_Steven_MD_420x504.jpg

First Name

Steven

Last Name

Herskovitz

NPI

1588749808

Faculty ID

5668

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Herskovitz is Professor of Clinical Neurology and Director of the EMG Lab / Neuromuscular division. He earned his medical degree from Cornell University Medical Center in 1980. He completed residencies in both Internal Medicine and Neurology, followed by a Fellowship in Electromyography/Neuromuscular Disorders,&nbsp;all at the Albert Einstein College of Medicine. He is a diplomate of the ABIM, ABPN, ABEM, and ABPN-AQNM. His clinical research interests include the peripheral neuropathies, entrapment neuropathies and peripheral&nbsp;neurotoxicology. He has published on various aspects of carpal tunnel syndrome including electrophysiologic diagnosis, treatment and autonomic features, clinical features of a variety of peripheral neuropathies, and the neurotoxicology of pharmaceutical and industrial agents. He is author of: <em>Herskovitz S, Scelsa S, Schaumburg HH. Peripheral Neuropathies in Clinical Practice. Contemporary Neurology Series. Oxford University Press. New York. 2010</em>. Two positions are available yearly in the clinical neurophysiology /EMG fellowship program.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Herskovitz focuses on the clinical and neurodiagnostic (EMG; neuromuscular ultrasound) evaluation of neuromuscular disorders.

Research Focus

Dr. Herskovitz's research is focused on the clinical and neurodiagnostic assessment of neuropathies.

Elsevier Profile

Selected Publications

<p><strong>Bibliography</strong><br /><br /><strong>A. Original Communications in Reviewed Journals:</strong></p>
<p>1. Lipton RB, Krupp L, Horoupian D, Herskovitz S, Arezzo JC, Kurtzberg D. Progressive multifocal leukoencephalopathy of the posterior fossa in an AIDS patient: Clinical, radiographic and evoked potential findings. European Neurology. 28:258?261,1988.</p>
<p>2. Herskovitz S, Lipton RB, Lantos G. NeuroBehcet's disease: CT and clinical correlates. Neurology. 38:1714?1720, 1988.</p>
<p>3. Herskovitz S, Siegel SE, Schneider AT, Nelson SJ, Goodrich JT, Lantos G. Spinal cord toxoplasmosis in AIDS. Neurology. 39:1552?1553, 1989.</p>
<p>4. Loh F, Herskovitz S, Berger AR, Swerdlow M. Brachial plexopathy associated with interleukin 2 therapy. Neurology. 42:462?463, 1992.</p>
<p>5. Newman LC, Herskovitz S, Lipton RB, Solomon S. Chronic paroxysmal headache: Two cases with cerebrovascular disease. Headache 32: 75?76, 1992.</p>
<p>6. Gonzales GR, Herskovitz S, Rosenblum M, et al. Dejerine Roussy syndrome caused by CNS toxoplasmosis in patients with AIDS. Neurology 42: 1107?1109, 1992.</p>
<p>7. Herskovitz S, Gordon M, Strauch B. Shiatsu massage induced injury of the median recurrent motor branch. Muscle &amp; Nerve 15 (10): 1215, 1992.</p>
<p>8. Herskovitz S, Loh F, Berger AR, Kucherov M. Erythromelalgia: Association with hereditary sensory neuropathy and response to amitriptyline. Neurology 43: 621?622, 1993.</p>
<p>9. Herskovitz S, Bieri P, Berger AR. Depressor septi nasi myokymia. Muscle &amp; Nerve 17: 116, 1994.</p>
<p>10. Strominger MB, Slamovits TL, Herskovitz S, Lipton RB. Transient worsening of optic neuropathy as a sequela of the Jarisch?Herxheimer reaction in the treatment of Lyme disease. J Neuro Ophthalmol 14(2): 77?80, 1994.</p>
<p>11. Scelsa SN,, Lipton RB, Sanders H, Herskovitz S. Headache characteristics in hospitalized patients with Lyme disease. Headache 35 (3): 125-130, 1995.</p>
<p>12. Berger AR, Herskovitz S, Kaplan J. Late motor involvement in cases presenting as chronic sensory demyelinating polyneuropathy. Muscle &amp; Nerve 18: 440-444, 1995.</p>
<p>13. Herskovitz S, Berger AR, Lipton, RB. Low dose, short-term oral prednisone in the treatment of carpal tunnel syndrome. Neurology 45: 1923-1925, 1995.</p>
<p>14. Berger AR, Herskovitz, S, Scelsa SN. Restoration of IVIg efficacy by plasma exchange in CIDP. Neurology 45: 1628-1629, 1995.</p>
<p>15. Oware A, Herskovitz S, Berger AR. Long thoracic nerve palsy associated with chiropractic manipulation. Neurology 18:1351, 1995.</p>
<p>16. Berger AR, Swerdlow M, Herskovitz S. Myasthenia gravis presenting with uncontrollable flatulence and urinary/fecal incontinence. Muscle &amp; Nerve 19: 113-114, 1996.</p>
<p>17. Scelsa SN, Berger AR, Herskovitz S. The diagnostic utility of F waves in L5/S1 radiculopathy. Muscle &amp; Nerve 18: 1496, 1995.</p>
<p>18. Scelsa SN, Herskovitz S, Berger AR. A predominantly motor polyradiculopathy of Lyme disease. Muscle &amp; Nerve 19: 780-783, 1996.</p>
<p>19. Scelsa SN, Herskovitz S, Bieri P, Berger AR. Median mixed and sensory conduction studies in carpal tunnel syndrome. Electroencephalography and Clinical Neurophysiology 109: 268-273, 1998</p>
<p>20. Scelsa SN, Herskovitz S, Reichler B. Treatment of Mononeuropathy Multiplex in Hepatitis C Virus and Cryoglobulinemia. Muscle &amp; Nerve 21: 1526-1529, 1998.</p>
<p>21. Scelsa SN, Herskovitz S. Miller Fisher syndrome: axonal, demyelinating or both? Electromyogr. Clin. Neurophysiol. 40: 497-502, 2000.</p>
<p>22. Manfredi PL, Herskovitz S, Folli F, Pigazzi A, Swerdlow ML. Spinal epidural abscess: treatment options. Eur Neurol 40:58-60, 1998.</p>
<p>23. Berger AR, Schaumburg HH, Freeman K, Gourevitch MN, Herskovitz S, Arezzo JC. Prevalence of peripheral neuropathy in injection drug users. Neurology 1999; 53: 592-597</p>
<p>24. Verghese J, Galanopoulou AS, Herskovitz S. Autonomic dysfunction in idiopathic carpal tunnel syndrome. Muscle &amp; Nerve 23: 1209-1213, 2000.</p>
<p>25. Scelsa S, Berger A, Herskovitz S. Electrophysiologic correlates of L5/S1 radiculopathy. Electromyogr. clin. Neurophysiol 2001, 41, 145-151.</p>
<p>26. Verghese J, Bieri PL, Gellido C, Schaumburg HH, Herskovitz S. Peripheral neuropathy in young-old and old-old patients. Muscle &amp; Nerve 24: 1476-1481, 2001.</p>
<p>27. Scelsa S, Ghali V, Herskovitz S, et al. Blood &atilde;&auml; T cells, Campylobacter jejuni, and GM1 titers in Guillain Barre syndrome. Muscle &amp; Nerve 30: 423-432, 2004.</p>
<p>28. Geyer H, Schaumburg HH, Herskovitz S. Methyl bromide intoxication causes reversible, symmetric, brainstem and cerebellar MRI lesions. Neurology 2005; 64:1279-1281.</p>
<p>29. Herskovitz S, Song H, Cozien D, Scelsa S. Sensory symptoms in acquired neuromyotonia. Neurology 2005;65:1330-1331.</p>
<p>30. Schaumburg HH, Herskovitz S, Cassano V. Occupational manganese neurotoxicity provoked by hepatitis C. Neurology 2006;67:322-3.</p>
<p>31. Blumenthal S, Herskovitz S, Verghese J. Carpal tunnel syndrome in older adults. Muscle &amp; Nerve 2006;34:78-83.</p>
<p>32. Schaumburg HH, Herskovitz S. Is acquired copper deficiency myeloneuropathy from denture cream use a clue to clioquinol-induced subacute myelo-optic neuropathy (SMON)? Neurology 2008; 71 (9):622.</p>
<p>33. Robbins MS, Roth S, Swerdlow ML, Bieri P, Herskovitz S. Optic neuritis and palatal dysarthria as presenting features of post-infectious GQ1b antibody syndrome. Clin Neurol Neurosurg 2009;111:465-466.</p>
<p>34. Issa SS, Herskovitz S, Lipton RB. Acquired neuromyotonia as a paraneoplastic manifestation of ovarian cancer. Neurology 2011;76:101-103 .</p>
<p><strong>B. Books, Chapters in Books, Editorials and Review Articles:</strong></p>
<p>1. Contributing author: Pousada, L, Osborn HH. Emergency Medicine for the House Officer. Williams and Wilkins, 1986. (chapters on headache and CPR).</p>
<p>2. Contributing author: Schaumburg HH, Berger AR, Thomas PK. Disorders of Peripheral Nerves, 2nd edition, F.A. Davis, 1992.</p>
<p>3. Berger AR, Herskovitz S. Cumulative trauma disorders and occupational nerve disease. In: Rosenberg, N ed. Occupational and Environmental Neurology. Butterworth-Heinemann, Boston, 1995.</p>
<p>4. Assistant Editor: Spencer PS, Schaumburg HH, Ludolph AC. Experimental and Clinical Neurotoxicology, 2nd edition. Oxford University Press, 2000.</p>
<p>5. Schaumburg HH, Herskovitz S. The Weak Child &ndash; A Cautionary Tale. N Engl J Med 2000 (editorial); 342, 127-129.</p>
<p>6. Herskovitz, S. Toxic neuropathies &ndash; Amiodarone, Gold, Perhexilene, Misonidazole. In Medlink Neurology (www.medlink.com), 2001/2002/2003/2004/2005/2006.</p>
<p>7. Herskovitz S, Schaumburg HH. Neuropathy due to drugs. In: Dyck PJ, Thomas PK, editors: Peripheral Neuropathy, 4th edition, 2005.</p>
<p>8. Herskovitz S, Scelsa S, Schaumburg HH. Peripheral Neuropathies in Clinical Practice.&nbsp;Contemporary Neurology Series. Oxford University Press. New York. 2010.</p>

EMR ID

3322

Biography

<p>Steven Herskovitz, MD, is Director, Neuromuscular Medicine and Director, Electromyography (EMG) Lab at Montefiore. He is also Professor of Neurology at our Albert Einstein College of Medicine. Dr. Herskovitz&rsquo;s clinical focus is on the evaluation and management of all neuromuscular disorders, with a particular interest in electrodiagnostic and neuromuscular ultrasound assessment.</p><p>In 1976, Dr. Herskovitz received his Bachelor of Science in biology at the State University of New York at Stony Brook. He then attended Cornell University Medical College, where he received his Doctor of Medicine in 1980. From 1980 to 1987, Dr. Herskovitz completed his postgraduate training at Montefiore. During this time, he spent his first year as a medical intern and next two years as a medical resident. In 1983, he began a three-year neurology residency, becoming Chief Resident in the final year. He ended his postgraduate training with a fellowship in Electromyography and Neuromuscular Diseases.</p><p>Expanding on his clinical focus, Dr. Herskovitz&rsquo;s research centers on clinical, electrodiagnostic and neuromuscular ultrasound assessment of neuropathies. His work has been published in many peer-reviewed journals, books, review articles and abstracts.</p><p>Dr. Herskovitz is board certified by the American Board of Internal Medicine, the American Board of Psychiatry and Neurology, including Added Qualification in Neuromuscular Medicine, and the American Board of Electrodiagnostic Medicine. He is a member of the American Academy of Neurology and the American Association of Neuromuscular and Electrodiagnostic Medicine.</p>

Is Open Scheduling

Off

Jonathan M. Gursky

https://assets.montefioreeinstein.org/profiles/images/physphoto/Gursky_Jonathan_MD_420x504.jpg

First Name

Jonathan

Last Name

Gursky

NPI

1275950487

Faculty ID

16181

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Gursky focuses on the various needs of epilepsy patients including issues related to medication management and driving.

Research Focus

Dr. Gursky's research focuses on seizure triggers in addition to seizure prediction and analysis. He is involved in various clinical trials investigating new potential therapies for epilepsy.&nbsp;

Elsevier Profile

EMR ID

13408

Biography

<p>Jonathan M. Gursky, MD, is an Attending Physician at Montefiore and Assistant Professor of Neurology at our Albert Einstein College of Medicine. His clinical focus is on the diagnosis and treatment of adults and adolescents with epilepsy and seizure disorders.</p><p>After earning his Bachelor of Science at Cornell University in 2010, Dr. Gursky attended the New York University School of Medicine, where he received his Doctor of Medicine in 2014. He began his postgraduate training in 2014 with a year-long internship in internal medicine at Icahn School of Medicine at Mount Sinai. He continued his training at this institution and completed a residency in neurology in 2018, becoming Chief Resident in his final year. In 2019, Dr. Gursky completed a fellowship in clinical neurophysiology at Montefiore.</p><p>Expanding on his clinical focus, Dr. Gursky&rsquo;s research examines the interactions between epilepsy with various neurological and general medical disorders. His findings have been published in peer-reviewed journals and articles and have been shared at national lectures and presentations.</p><p>Dr. Gursky holds additional clinical interests in the effects of epilepsy on mental and behavioral health.</p><p>Dr. Gursky is a member of the American Academy of Neurology, the American Clinical Neurophysiology Society and the American Epilepsy Society and is board certified by the American Board of Psychiatry and Neurology. </p>

Is Open Scheduling

Off

Aristea S. Galanopoulou

https://assets.montefioreeinstein.org/profiles/images/physphoto/Galanopoulou_Aristea_MD_420x504.jpg

First Name

Aristea

Last Name

Galanopoulou

NPI

1891870580

Faculty ID

6874

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>The maturation of GABA_A<span class="apple-converted-space">&nbsp;</span>receptor-mediated signaling from depolarizing to inhibitory is an age-related process controlled by cation chloride cotransporters, such as KCC2. As a result, GABA exerts dual functions, being an important neurotrophic factor during early development and the principal inhibitory neurotransmitter of the mature central nervous system. In our laboratory we have been investigating the age mechanisms through which early life stressors and seizures may disrupt the normal patterns of brain development, by disrupting the neurotrophic effects of GABA. We are also studying methods to reverse these adverse processes. Furthermore, we are very interested in understanding how epileptogenesis proceeds in the developing brain and what is the specific role of GABA_A<span class="apple-converted-space">&nbsp;</span>receptors in this process.</p>
<p>To better understand the pathophysiology and design better methods to treat catastrophic early life epilepsies, we are developing and studying new models of early life epilepsy. These include models of symptomatic infantile spasms that recapitulate most of the features of the human condition. Several projects are under way to (a) elucidate the pathophysiology of infantile spasms, and (b) conduct preclinical trials to find better treatments for spasms and the associated comorbidities. Our studies have provided preclinical evidence for new potential treatments with disease modifying properties for these early life epileptic encephalopathies, such as mTOR inhibitor, carisbamate and a new vigabatrin analog.</p>
<p>Post-traumatic epilepsy is a common consequence of traumatic brain injury leading to high morbidity and morbidity. Our lab is participating in an international multicenter preclinical consortium, EpiBioS4Rx, leading efforts to develop better therapies for post-traumatic epilepsy. We use a rodent model of traumatic brain injury to identify targets and test for better therapies, through a combination of expression studies, in vivo behavioral and electrophysiologic monitoring and therapy screening to identify antiepileptogenic compounds. Furthermore, through a separate project, we are looking into factors predicting epilepsy and behavioral outcomes after traumatic brain injury.</p>
<p>Genetic etiologies are often identified in patients with epilepsies. Our lab has been investigating genes involved in lissencephaly associated epilepsies and developmental disorders as well as Rett syndrome which is due to MeCP2 gene mutations. Through the use of mouse models we have been investigating genotype-phenotype correlations and mechanisms involved with the ultimate goal of testing therapies.</p>
<p>Students interested in these projects will gain exposure to a variety of<span class="apple-converted-space">&nbsp;</span><em>in vivo</em><span class="apple-converted-space">&nbsp;</span>and<span class="apple-converted-space">&nbsp;</span><em>in vitro</em><span class="apple-converted-space">&nbsp;</span>techniques that combine molecular biology<em>, in vivo</em><span class="apple-converted-space">&nbsp;</span>and<span class="apple-converted-space">&nbsp;</span><em>in vitro</em><span class="apple-converted-space">&nbsp;</span>electrophysiology, histological, and behavioral studies and will be involved in projects with direct translational relevance to the clinical practice, i.e. identification of novel therapies.&nbsp;</p>
<p>&nbsp;</p>
<p><!--EndFragment--></p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Adult epileptology, clinical neurophysiology

Research Focus

Post-traumatic epilepsy, developmental and epileptic encephalopathies, infantile spasms, GABA receptors, biomarkers, treatments for epilepsies

Elsevier Profile

Selected Publications

<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">1.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Galanopoulou AS: &ldquo;Dissociated gender-specific effects of recurrent seizures on GABA signaling in CA1 pyramidal neurons: role of GABA_A&nbsp;receptors&rdquo;: J Neurosci 28 (7): 1557-67 (2008). PMID 18272677. https://www.jneurosci.org/content/28/7/1557.long</span></p&gt;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">2.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Briggs SW, Mowrey W, Hall CB,<strong>&nbsp;</strong>Galanopoulou AS<strong>.&nbsp;</strong>CPP-115, a vigabatrin analogue, decreases spasms in the multiple-hit rat model of infantile spasms. Epilepsia (2014) 55(1):94-102. PMID 24321005.&nbsp;https://onlinelibrary.wiley.com/doi/full/10.1111/epi.12424&nbsp;</span>…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">3.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Galanopoulou AS&nbsp;and Mosh&eacute; SL. Pathogenesis and new candidate treatments for infantile spasms and early life epileptic encephalopathies: a view from preclinical studies. Neurobiology of Disease (2015): Neurobiol Dis. 2015 Jul;79:135-49. PMID 25968935.&nbsp;&nbsp;https://www.sciencedirect.com/science/article/pii/S096999611500162X?via…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">4.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Galanopoulou AS, Mowrey WB, Liu W, Li Q, Shandra O, Moshe SL.&nbsp;</span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Preclinical Screening for Treatments for Infantile Spasms in the Multiple Hit Rat Model of Infantile Spasms: An Update. Neurochem Res. 2017;42:1949-61.&nbsp;PMID 28462453.&nbsp;&nbsp;https://link.springer.com/article/10.1007%2Fs11064-017-2282-0</span></p…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">5.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Galanopoulou AS, French JA, O&rsquo;Brien T, Simonato M. &ldquo;Harmonization in preclinical epilepsy research: a joint AES/ILAE translational initiative&rdquo;. Epilepsia (2017) 58 (Suppl 4):7-9. PMID 29105072. https://onlinelibrary.wiley.com/doi/full/10.1111/epi.13921</span></p&gt;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">6.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Ono T, Wagenaar J, Giorgi FS et al, Galanopoulou AS. A companion to the preclinical common data elements and case report forms for rodent EEG studies. A report of the TASK3 EEG Working Group of the ILAE/AES Joint Translational Task Force. Epilepsia Open. 2018;3:90-103. PMID 30450486. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210053/pdf/EPI4-3-90.pdf<…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">7.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Akman O, Raol YH, Auvin S et al, Galanopoulou AS.&nbsp;</span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Methodologic recommendations and possible interpretations of video-EEG recordings in immature&nbsp;rodents used as experimental controls: A&nbsp;TASK1-WG2 report of the ILAE/AES Joint Translational&nbsp;Task Force. Epilepsia Open. (2018)&nbsp;vol 3: 437-459. PMID 30525114. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276777/pdf/EPI4-3-437.pdf…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">8.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Katsarou AM, Li, Q, Liu W, Mosh&eacute; SL, Galanopoulou AS.&nbsp;</span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">&ldquo;Acquired parvalbumin-selective interneuronopathy in the multiple-hit model of infantile spasms: a putative basis for the partial responsiveness to vigabatrin analogs?&rdquo; Epilepsia Open (2018) vol 3 (S2): 155-164. PMID 30564774. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293059/pdf/EPI4-3-155.pdf…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">9.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Salar S, Moshe SL, Galanopoulou AS. Metabolic etiologies in West syndrome.&nbsp;</span><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Epilepsia Open. 2018;3:134-66.</span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;"><a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/29881795"><span lang="PT-BR">https://www.ncbi.nlm.nih.gov/pubmed/29881795</span></a></span></p&gt;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">10.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Saletti PG, Ali I, Casillas-Espinosa PM et al, Galanopoulou AS.&nbsp;</span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">In search of antiepileptogenic treatments for post-traumatic epilepsy. Neurobiol Dis. (2019)&nbsp;123: 86-99 (2019).&nbsp; PMID: 29936231.&nbsp;<a style="color: #954f72; text-decoration: underline;" href="https://www.sciencedirect.com/science/article/pii/S0969996118301980?via…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">11.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Galanopoulou AS, Ferastraoaru V, Correa DJ, Cherian K, Duberstein S, Gursky J, Hanumanthu R, Hung C, Molinero I, Khodakivska O, Legatt AD, Patel P, Rosengard J, Rubens E, Sugrue W, Yozawitz E, Mehler MF, Ballaban-Gil K, Haut SR, Moshe SL, Boro A. EEG findings in acutely ill patients investigated for SARS-CoV-2/COVID-19: A small case series preliminary report. Epilepsia Open. 2020;5:314-24.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/32537529">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">12.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif;">Parihar R, Ferastraoaru V, Galanopoulou AS, Geyer HL, Kaufman DM.&nbsp;</span><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Outcome of Hospitalized Parkinson's Disease Patients with and without COVID-19. Mov Disord Clin Pract. 2021;8:859-67.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/34226870">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">13.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Akman O, Briggs SW, Mowrey WB, Moshe SL, Galanopoulou AS. Antiepileptogenic effects of rapamycin in a model of infantile spasms due to structural lesions. Epilepsia. 2021;62:1985-99.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/34212374">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">14.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Galanopoulou AS, Loscher W, Lubbers L, O'Brien TJ, Staley K, Vezzani A, D'Ambrosio R, White HS, Sontheimer H, Wolf JA, Twyman R, Whittemore V, Wilcox KS, Klein B. Antiepileptogenesis and disease modification: Progress, challenges, and the path forward-Report of the Preclinical Working Group of the 2018 NINDS-sponsored antiepileptogenesis and disease modification workshop. Epilepsia Open. 2021;6:276-96.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/34033232">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">15.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Katsarou AM, Kubova H, Auvin S, Mantegazza M, Barker-Haliski M, Galanopoulou AS, Reid CA, Semple BD.&nbsp;</span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">A companion to the preclinical common data elements for rodent models of pediatric acquired epilepsy: A report of the TASK3-WG1B, Pediatric and Genetic Models Working Group of the ILAE/AES Joint Translational Task Force. Epilepsia Open. 2022.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/35950641">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">16.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Medel-Matus JS, Lagishetty V, Santana-Gomez C, Shin D, Mowrey W, Staba RJ, Galanopoulou AS, Sankar R, Jacobs JP, Mazarati AM. Susceptibility to epilepsy after traumatic brain injury is associated with preexistent gut microbiome profile. Epilepsia. 2022;63:1835-48.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/35366338">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">17.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Saletti PG, Mowrey WB, Liu W, Li Q, McCullough J, Aniceto R, Lin IH, Eklund M, Casillas-Espinosa PM, Ali I, Santana-Gomez C, Coles L, Shultz SR, Jones N, Staba R, O'Brien TJ, Moshe SL, Agoston DV, Galanopoulou AS, EpiBio SRSG. Early preclinical plasma protein biomarkers of brain trauma are influenced by early seizures and levetiracetam. Epilepsia Open. 2023;8:586-608.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/37026764">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">18.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Coles L, Forcelli PA, Leclercq K, Katsarou AM, Klein BD, Potschka H, Koehling R, Harte-Hargrove L, Galanopoulou AS, Metcalf CS. Preclinical common data elements for general pharmacological studies (pharmacokinetic sample collection, tolerability, and drug administration). A report of the TASK3-WG1A General Pharmacology Working Group of the ILAE/AES Joint Translational Task Force. Epilepsia Open. 2023.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/36896626">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">19.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Guerrini R, Conti V, Mantegazza M, Balestrini S, Galanopoulou AS, Benfenati F. Developmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum. Physiol Rev. 2023;103:433-513.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/35951482">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">20.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Auvin S, Galanopoulou AS, Moshe SL, Potschka H, Rocha L, Walker MC. Revisiting the concept of drug-resistant epilepsy: A TASK1 report of the ILAE/AES Joint Translational Task Force. Epilepsia. 2023;64:2891-908.&nbsp;<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/37676719">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">21.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Grandizoli Saletti P, Casillas-Espinosa PM, Panagiotis Lisgaras C, Bi Mowrey W, Li Q, Liu W, Brady RD, Ali I, Silva J, Yamakawa G, Hudson M, Li C, Braine EL, Coles L, Cloyd JC, Jones NC, Shultz SR, Moshe SL, O'Brien TJ, Galanopoulou AS. Tau Phosphorylation Patterns in the Rat Cerebral Cortex After Traumatic Brain Injury and Sodium Selenate Effects: An Epibios4rx Project 2 Study. J Neurotrauma. 2024;41:222-43.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/36950806">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">22.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Lucasius C, Grigorovsky V, Nariai H, Galanopoulou AS, Gursky J, Moshe SL, Bardakjian BL. Biomimetic Deep Learning Networks With Applications to Epileptic Spasms and Seizure Prediction. IEEE Trans Biomed Eng. 2024;71:1056-67.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/37851549">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">23.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif;">Samfira IMA, Galanopoulou AS, Nariai H, Gursky JM, Moshe SL, Bardakjian BL.&nbsp;</span><span style="font-size: 9pt; font-family: Verdana, sans-serif;">EEG-based spatiotemporal dynamics of fast ripple networks and hubs in infantile epileptic spasms. Epilepsia Open. 2024;9:122-37.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/37743321">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">24.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Perucca E, French JA, Aljandeel G, Balestrini S, Braga P, Burneo JG, Felli AC, Cross JH, Galanopoulou AS, Jain S, Jiang Y, Kalviainen R, Lim SH, Meador KJ, Mogal Z, Nabbout R, Sofia F, Somerville E, Sperling MR, Triki C, Trinka E, Walker MC, Wiebe S, Wilmshurst JM, Wirrell E, Yacubian EM, Kapur J. Which terms should be used to describe medications used in the treatment of seizure disorders? An ILAE position paper. Epilepsia. 2024;65:533-41.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/38279786">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">25.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Pease M, Gupta K, Moshe SL, Correa DJ, Galanopoulou AS, Okonkwo DO, Gonzalez-Martinez J, Shutter L, Diaz-Arrastia R, Castellano JF.&nbsp;</span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Insights into epileptogenesis from post-traumatic epilepsy. Nat Rev Neurol. 2024;20:298-312.&nbsp;<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/38570704">https://www.ncbi.nlm.nih…;
<p></p>
<p class="MsoNormal" style="font-size: medium;"><span style="font-size: 9pt; font-family: Verdana, sans-serif;">&nbsp;</span></p>

EMR ID

4043

Is Open Scheduling

Off